Pharmacokinetics of oral zidovudine administered during labour: A preliminary study

HIV Medicine

Volumn 8, Issue 7, 2007, Pages 451-456

  Mirochnick, Mark ^a,l   Rodman, J H ^b   Robbins, B L ^b   Fridland, A ^b   Gandia J ^c   Hitti, J ^d   Bardeguez, A ^e   Rathore, M H ^f   Gonzalez Garcia, A ^g   Cababasay, M ^h   Samson, P ^h   Mofenson, L ⁱ   Bryson, Y J ^j   Dorenbaum, A ^k  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c San Juan City Hospital   (Puerto Rico)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l BOSTON MEDICAL CENTER   (United States)

more..

Author keywords

AIDS; Antiretrovirals; Pharmacokinetics; Pregnancy

Indexed keywords

ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILDBIRTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PREGNANT WOMAN; PRIORITY JOURNAL; SAMPLE SIZE; VIRUS TRANSMISSION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LABOR, OBSTETRIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 34548301133     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00495.x     Document Type: Article

References (19)

1. Watts H. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002; 346: 1879-1891.
2. Connor EM, Sperling RS, Gelber R. et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
3. Cooper ER, Charurat M, Mofenson L. et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-494.
4. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial. Lancet 1999; 353: 1035-1039.
5. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-987.
6. Dabis F, Msellati P, Meda N. et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mere-Enfant. Lancet 1999; 353: 786-792.
7. Shaffer N, Chuachoowong R, Mock PA. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353: 773-780.
8. Wiktor SZ, Ekpini E, Karon JM. et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 1999; 353: 781-785.
9. O'Sullivan MJ, Boyer PJ, Scott GB. et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168: 1510-1516.
10. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: Pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000; 39: 281-293.
11. Robbins BL, Waibel BH, Fridland A. et al. Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. Antimicrob Agents Chemother 1996; 40: 2651-2654.
12. D'Argenio D, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource, 1997.
13. Rodman JH, Flynn PM, Robbins B. et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis 1999; 180: 1844-1850.
14. US Department of Health and Human Services. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. http://aidsinfo.nih.gov/guidelines 2006.
15. De Cock KM, Fowler MG, Mercier E. et al. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. J Am Med Assoc 2000; 283: 1175-1182.
16. Barry MG, Khoo SH, Veal GJ. et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10: 1361-1367.
17. Sale M, Sheiner LB, Volberding P, Blaschke TF. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993; 54: 556-566.
18. Bhadrakom C, Simonds RJ, Mei JV. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: Tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 2000; 14: 509-516.
19. Moodley J, Moodley D, Pillay K. et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-1333.